8 Jul 2020 07:00
08 July 2020
RNS REACH
Open Orphan Plc
("Open Orphan" or the "Company")
Upcoming Investor Events
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models is delighted to be attending and presenting at a series of investor events from the 9th to 11th July 2020.
Cathal Friel, Open Orphan's Chief Executive Officer, will be in attendance for all of the events and will be presenting to update existing and potential investors on the Company's business plans for 2020-2021.
No new material information will be disclosed at any event.
A full schedule of the upcoming events is as follows:
Event | Date/Time | Location |
Hardman & Co Investor Forum Webinar | July 9th 2020 / 15:00 - 16:30 | Virtual Event, further information and registration here: Link |
Proactive Investors One2One Investor Forum | July 9th 2020 / 18:00 - 20:00 | Virtual Event, further information and registration here: Link |
Mello Virtual - Investing in the New World | July 11th 2020 / 9:00 - 17:00 | Virtual Event, further information and registration here: Link |
For further information please contact
Open Orphan plc | +353 (0)1 644 0007 |
Cathal Friel, Executive Chairman | |
Arden Partners plc (Nominated Adviser and Joint Broker) | +44 (0)20 7614 5900 |
John Llewellyn-Lloyd / Benjamin Cryer / Dan Gee-Summons | |
finnCap plc (Joint Broker) | +44 (0) 20 7220 500 |
Geoff Nash / James Thompson/ Richard Chambers | |
Davy (Euronext Growth Adviser and Joint Broker) | +353 (0)1 679 6363 |
Anthony Farrell | |
Camarco (Financial PR) | +44 (0)20 3757 4980 |
Tom Huddart / Hugo Liddy |
Notes to Editors - Open Orphan:
Open Orphan is a rapidly growing niche CRO pharmaceutical services group which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe's only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms and connected to our specialist laboratory facility. Which offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development. Reliable laboratory analysis underpinned by scientific expertise is essential when processing and analysing clinical samples. Robust quality processes support our team of scientists in the delivery of submission ready data.
The Group has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. As announced in early March, Open Orphan is rapidly advancing a number of Coronavirus challenge study models and expects to be helping many COVID-19 vaccine development companies to test their vaccines. No other company in the world has such a portfolio, with only two competitors globally having 1 challenge study model each. In June 2020 hVIVO COVID Clear Test was launched, the most accurate antibody test available to UK employers, helping them to get their people back to work.
Open Orphan comprises of two commercial specialist CRO services businesses, hVIVO and Venn Life Sciences, and is developing an early stage orphan drug genomics data platform business. This platform captures valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls), preclinical, Phase I & II clinical trials design and execution. The merger with hVIVO created a European full pharma services group broadening the Group's customer base and with complementary specialist CRO services, widened the range of the Group's service offerings.